Dr. Barry R. Davis, the Guy S. Parcel Chair in Public Health and professor in the department of biostatistics and data science at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been re-appointed to the Federal Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee as a statistician for the panel. The committee reviews and evaluates data concerning the safety and effectiveness of drugs for use in the treatment of cardiovascular and renal disorders and then makes recommendations to the Commissioner of Food and Drug Products. The Cardiovascular and Renal Drugs Advisory Committee is one division of the FDA’s Center for Drug Evaluation Research.
[Photo: Dr. Barry R. Davis]
Dr. Davis originally was recommended and selected in 2015 for the four-year appointment with the FDA based upon his work in the design and analysis of clinical trials and his long-standing participation in major cardiovascular clinical trials. He has been selected for a second four-year appointment and will continue to represent the field of biostatistics on the committee, which also includes experts in cardiology, internal medicine, nephrology, electrophysiology, clinical trial design, cardiovascular medicine and coronary artery disease.
Dr. Davis also directs the school’s Coordinating Center for Clinical Trials (CCCT). The goal of the center is to identify important public health problems and design large clinical trials to study the efficacy of appropriate interventions, including the collection, management, reporting and interpretation of study findings. The CCCT has designed studies on cardiovascular disease, diabetes, sickle cell anemia and the use of blood products in a trauma setting.
Dr. Davis earned his MD from the University of California San Diego School of Medicine and his PhD and master’s degree in applied mathematics from Brown University. He has been a faculty member at UTHealth School of Public Health since 1983.